A citation-based method for searching scientific literature

William J Sandborn, Christopher Gasink, Long-Long Gao, Marion A Blank, Jewel Johanns, Cynthia Guzzo, Bruce E Sands, Stephen B Hanauer, Stephan Targan, Paul Rutgeerts, Subrata Ghosh, Willem J S de Villiers, Remo Panaccione, Gordon Greenberg, Stefan Schreiber, Simon Lichtiger, Brian G Feagan. N Engl J Med 2012
Times Cited: 731







List of co-cited articles
955 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Brian G Feagan, William J Sandborn, Christopher Gasink, Douglas Jacobstein, Yinghua Lang, Joshua R Friedman, Marion A Blank, Jewel Johanns, Long-Long Gao, Ye Miao,[...]. N Engl J Med 2016
821
62

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
Bruce E Sands, William J Sandborn, Remo Panaccione, Christopher D O'Brien, Hongyan Zhang, Jewel Johanns, Omoniyi J Adedokun, Katherine Li, Laurent Peyrin-Biroulet, Gert Van Assche,[...]. N Engl J Med 2019
342
33

Vedolizumab as induction and maintenance therapy for Crohn's disease.
William J Sandborn, Brian G Feagan, Paul Rutgeerts, Stephen Hanauer, Jean-Frédéric Colombel, Bruce E Sands, Milan Lukas, Richard N Fedorak, Scott Lee, Brian Bressler,[...]. N Engl J Med 2013
32

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease.
William J Sandborn, Brian G Feagan, Richard N Fedorak, Ellen Scherl, Mark R Fleisher, Seymour Katz, Jewel Johanns, Marion Blank, Paul Rutgeerts. Gastroenterology 2008
553
31

Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, William J Sandborn, Gert Van Assche, Jeffrey Axler, Hyo-Jong Kim, Silvio Danese,[...]. N Engl J Med 2013
23

Infliximab, azathioprine, or combination therapy for Crohn's disease.
Jean Frédéric Colombel, William J Sandborn, Walter Reinisch, Gerassimos J Mantzaris, Asher Kornbluth, Daniel Rachmilewitz, Simon Lichtiger, Geert D'Haens, Robert H Diamond, Delma L Broussard,[...]. N Engl J Med 2010
19

Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease.
Omoniyi J Adedokun, Zhenhua Xu, Christopher Gasink, Douglas Jacobstein, Philippe Szapary, Jewel Johanns, Long-Long Gao, Hugh M Davis, Stephen B Hanauer, Brian G Feagan,[...]. Gastroenterology 2018
114
17

Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
Robert Battat, Uri Kopylov, Talat Bessissow, Alain Bitton, Albert Cohen, Anjali Jain, Myriam Martel, Ernest Seidman, Waqqas Afif. Clin Gastroenterol Hepatol 2017
132
17

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
William J Sandborn, Chinyu Su, Bruce E Sands, Geert R D'Haens, Séverine Vermeire, Stefan Schreiber, Silvio Danese, Brian G Feagan, Walter Reinisch, Wojciech Niezychowski,[...]. N Engl J Med 2017
660
16

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Bruce E Sands, Brian G Feagan, Paul Rutgeerts, Jean-Frédéric Colombel, William J Sandborn, Richmond Sy, Geert D'Haens, Shomron Ben-Horin, Jing Xu, Maria Rosario,[...]. Gastroenterology 2014
426
15

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Stephen B Hanauer, Brian G Feagan, Gary R Lichtenstein, Lloyd F Mayer, S Schreiber, Jean Frederic Colombel, Daniel Rachmilewitz, Douglas C Wolf, Allan Olson, Weihang Bao,[...]. Lancet 2002
15

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean-Frédéric Colombel, William J Sandborn, Paul Rutgeerts, Robert Enns, Stephen B Hanauer, Remo Panaccione, Stefan Schreiber, Dan Byczkowski, Ju Li, Jeffrey D Kent,[...]. Gastroenterology 2007
14

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Brian G Feagan, William J Sandborn, Geert D'Haens, Julián Panés, Arthur Kaser, Marc Ferrante, Edouard Louis, Denis Franchimont, Olivier Dewit, Ursula Seidler,[...]. Lancet 2017
254
14

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
S R Targan, S B Hanauer, S J van Deventer, L Mayer, D H Present, T Braakman, K L DeWoody, T F Schaible, P J Rutgeerts. N Engl J Med 1997
14

Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents.
Pauline Wils, Yoram Bouhnik, Pierre Michetti, Bernard Flourie, Hedia Brixi, Anne Bourrier, Matthieu Allez, Bernard Duclos, Jean-Charles Grimaud, Anthony Buisson,[...]. Clin Gastroenterol Hepatol 2016
123
13

Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort.
Sam Khorrami, Daniel Ginard, Ignacio Marín-Jiménez, María Chaparro, Mónica Sierra, Mariam Aguas, Beatriz Sicilia, Valle García-Sánchez, Cristina Suarez, Albert Villoria,[...]. Inflamm Bowel Dis 2016
105
13

Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
Vince B C Biemans, Andrea E van der Meulen-de Jong, Christine J van der Woude, Mark Löwenberg, Gerard Dijkstra, Bas Oldenburg, Nanne K H de Boer, Sander van der Marel, Alexander G L Bodelier, Jeroen M Jansen,[...]. J Crohns Colitis 2020
66
19

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
L Peyrin-Biroulet, W Sandborn, B E Sands, W Reinisch, W Bemelman, R V Bryant, G D'Haens, I Dotan, M Dubinsky, B Feagan,[...]. Am J Gastroenterol 2015
13

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.
Fernando Gomollón, Axel Dignass, Vito Annese, Herbert Tilg, Gert Van Assche, James O Lindsay, Laurent Peyrin-Biroulet, Garret J Cullen, Marco Daperno, Torsten Kucharzik,[...]. J Crohns Colitis 2017
13

Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
Paul Rutgeerts, Christopher Gasink, Daphne Chan, Yinghua Lang, Paul Pollack, Jean-Frederic Colombel, Douglas C Wolf, Douglas Jacobstein, Jewel Johanns, Philippe Szapary,[...]. Gastroenterology 2018
80
16

IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.
Stephen B Hanauer, William J Sandborn, Brian G Feagan, Christopher Gasink, Douglas Jacobstein, Bin Zou, Jewel Johanns, Omoniyi J Adedokun, Bruce E Sands, Paul Rutgeerts,[...]. J Crohns Colitis 2020
72
16

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
Joana Torres, Stefanos Bonovas, Glen Doherty, Torsten Kucharzik, Javier P Gisbert, Tim Raine, Michel Adamina, Alessandro Armuzzi, Oliver Bachmann, Palle Bager,[...]. J Crohns Colitis 2020
297
12

Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts, William J Sandborn, Brian G Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Suzanne Travers, Daniel Rachmilewitz, Stephen B Hanauer, Gary R Lichtenstein,[...]. N Engl J Med 2005
12

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.
Bruce E Sands, Jingjing Chen, Brian G Feagan, Mark Penney, William A Rees, Silvio Danese, Peter D R Higgins, Paul Newbold, Raffaella Faggioni, Kaushik Patra,[...]. Gastroenterology 2017
153
11

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
Stephen B Hanauer, William J Sandborn, Paul Rutgeerts, Richard N Fedorak, Milan Lukas, Donald MacIntosh, Remo Panaccione, Douglas Wolf, Paul Pollack. Gastroenterology 2006
11

Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease--the McGill experience.
U Kopylov, W Afif, A Cohen, A Bitton, G Wild, T Bessissow, J Wyse, T Al-Taweel, A Szilagyi, E Seidman. J Crohns Colitis 2014
104
10

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Nicholas A Kennedy, Graham A Heap, Harry D Green, Benjamin Hamilton, Claire Bewshea, Gareth J Walker, Amanda Thomas, Rachel Nice, Mandy H Perry, Sonia Bouri,[...]. Lancet Gastroenterol Hepatol 2019
235
10

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.
Remo Panaccione, Subrata Ghosh, Stephen Middleton, Juan R Márquez, Boyd B Scott, Laurence Flint, Hubert J F van Hoogstraten, Annie C Chen, Hanzhe Zheng, Silvio Danese,[...]. Gastroenterology 2014
561
10

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
William J Sandborn, Paul Rutgeerts, Robert Enns, Stephen B Hanauer, Jean-Frédéric Colombel, Remo Panaccione, Geert D'Haens, Ju Li, Marie R Rosenfeld, Jeffrey D Kent,[...]. Ann Intern Med 2007
719
10

Crohn's disease.
Joana Torres, Saurabh Mehandru, Jean-Frédéric Colombel, Laurent Peyrin-Biroulet. Lancet 2017
780
10

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn,[...]. Lancet 2013
511
9

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Craig L Leonardi, Alexa B Kimball, Kim A Papp, Newman Yeilding, Cynthia Guzzo, Yuhua Wang, Shu Li, Lisa T Dooley, Kenneth B Gordon. Lancet 2008
9

The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Jean-Frédéric Colombel, Bruce E Sands, Paul Rutgeerts, William Sandborn, Silvio Danese, Geert D'Haens, Remo Panaccione, Edward V Loftus, Serap Sankoh, Irving Fox,[...]. Gut 2017
426
9

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.
Séverine Vermeire, Stefan Schreiber, Robert Petryka, Tanja Kuehbacher, Xavier Hebuterne, Xavier Roblin, Maria Klopocka, Adrian Goldis, Maria Wisniewska-Jarosinska, Andrey Baranovsky,[...]. Lancet 2017
238
9

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.
Siew C Ng, Hai Yun Shi, Nima Hamidi, Fox E Underwood, Whitney Tang, Eric I Benchimol, Remo Panaccione, Subrata Ghosh, Justin C Y Wu, Francis K L Chan,[...]. Lancet 2017
9

ACG Clinical Guideline: Management of Crohn's Disease in Adults.
Gary R Lichtenstein, Edward V Loftus, Kim L Isaacs, Miguel D Regueiro, Lauren B Gerson, Bruce E Sands. Am J Gastroenterol 2018
483
9

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Bruce E Sands, Laurent Peyrin-Biroulet, Edward V Loftus, Silvio Danese, Jean-Frédéric Colombel, Murat Törüner, Laimas Jonaitis, Brihad Abhyankar, Jingjing Chen, Raquel Rogers,[...]. N Engl J Med 2019
231
9

Infliximab maintenance therapy for fistulizing Crohn's disease.
Bruce E Sands, Frank H Anderson, Charles N Bernstein, William Y Chey, Brian G Feagan, Richard N Fedorak, Michael A Kamm, Joshua R Korzenik, Bret A Lashner, Jane E Onken,[...]. N Engl J Med 2004
9

Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
Bram Verstockt, Erwin Dreesen, Maja Noman, An Outtier, Nathalie Van den Berghe, Isolde Aerden, Griet Compernolle, Gert Van Assche, Ann Gils, Séverine Vermeire,[...]. J Crohns Colitis 2019
51
17

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
Wolfgang Hueber, Bruce E Sands, Steve Lewitzky, Marc Vandemeulebroecke, Walter Reinisch, Peter D R Higgins, Jan Wehkamp, Brian G Feagan, Michael D Yao, Marek Karczewski,[...]. Gut 2012
939
9

IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.
Alexander R Moschen, Herbert Tilg, Tim Raine. Nat Rev Gastroenterol Hepatol 2019
156
9

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Brian G Feagan, Julián Panés, Marc Ferrante, Arthur Kaser, Geert R D'Haens, William J Sandborn, Edouard Louis, Markus F Neurath, Denis Franchimont, Olivier Dewit,[...]. Lancet Gastroenterol Hepatol 2018
86
10

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.
Dan Turner, Amanda Ricciuto, Ayanna Lewis, Ferdinando D'Amico, Jasbir Dhaliwal, Anne M Griffiths, Dominik Bettenworth, William J Sandborn, Bruce E Sands, Walter Reinisch,[...]. Gastroenterology 2021
236
9

Effectiveness and safety of Ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies.
Fabio Salvatore Macaluso, Marcello Maida, Marco Ventimiglia, Mario Cottone, Ambrogio Orlando. Expert Opin Biol Ther 2020
20
40

Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
Claire Liefferinckx, Bram Verstockt, Ann Gils, Maja Noman, Catherine Van Kemseke, Elisabeth Macken, Martine De Vos, Wouter Van Moerkercke, Jean-Francois Rahier, Peter Bossuyt,[...]. J Crohns Colitis 2019
45
17

Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases.
Julien Kirchgesner, Magali Lemaitre, Fabrice Carrat, Mahmoud Zureik, Franck Carbonnel, Rosemary Dray-Spira. Gastroenterology 2018
248
8

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.
W J Sandborn, S B Hanauer, P Rutgeerts, R N Fedorak, M Lukas, D G MacIntosh, R Panaccione, D Wolf, J D Kent, B Bittle,[...]. Gut 2007
730
8

Certolizumab pegol for the treatment of Crohn's disease.
William J Sandborn, Brian G Feagan, Simeon Stoinov, Pieter J Honiball, Paul Rutgeerts, David Mason, Ralph Bloomfield, Stefan Schreiber. N Engl J Med 2007
779
8

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Konstantinos Papamichael, Adam S Cheifetz, Gil Y Melmed, Peter M Irving, Niels Vande Casteele, Patricia L Kozuch, Laura E Raffals, Leonard Baidoo, Brian Bressler, Shane M Devlin,[...]. Clin Gastroenterol Hepatol 2019
121
8

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.
William J Sandborn, Brian G Feagan, Douglas C Wolf, Geert D'Haens, Severine Vermeire, Stephen B Hanauer, Subrata Ghosh, Heather Smith, Matthew Cravets, Paul A Frohna,[...]. N Engl J Med 2016
261
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.